{"id":269707,"date":"2026-02-05T23:11:09","date_gmt":"2026-02-05T23:11:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/269707\/"},"modified":"2026-02-05T23:11:09","modified_gmt":"2026-02-05T23:11:09","slug":"novo-nordisk-vows-legal-action-to-protect-wegovy-pill","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/269707\/","title":{"rendered":"Novo Nordisk vows legal action to protect Wegovy pill"},"content":{"rendered":"

\"Shares Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices (Mads Claus Rasmussen) \u00b7 Mads Claus Rasmussen\/Ritzau Scanpix\/AFP <\/p>\n

Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.<\/p>\n

The Danish company only began selling Wegovy in pill form last month after having received approval from the US Food and Drug Administration, but the telehealth company Hims & Hers has begun advertising cheaper versions.<\/p>\n

“This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products,” said Novo Nordisk in a statement, referring to the hormone in Wegovy that regulates blood glucose levels and appetite.<\/p>\n

“Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework,” it added.<\/p>\n

Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called “compound” or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.<\/p>\n

That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.<\/p>\n

Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices.<\/p>\n

ef\/rl\/jj<\/p>\n","protected":false},"excerpt":{"rendered":"Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in…\n","protected":false},"author":2,"featured_media":269708,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[134,152992,524,111,139,14332,69,152993],"class_list":["post-269707","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-mads-claus-rasmussen","tag-medication","tag-new-zealand","tag-newzealand","tag-novo-nordisk","tag-nz","tag-regulatory-action"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/269707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=269707"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/269707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/269708"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=269707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=269707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=269707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}